Nci h522

HUVEC-C, 143B, A-549, HeLa, U2OS, and 4T1 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Caki-1, DU145, HT-29, HCT 116, MCF-7, NCI-H23, NCI-H522, NCI-H460, PC-3, SK-MEL-2, SK-MEL-5, SK-MEL-28, U-87MG, CT-26, and RenCa were obtained from the Korean Cell Line Bank (KCLB, Seoul, Korea). The cells were maintained with ATCC and KCLB recommended media, respectively, and supplemented with 10% fetal bovine serum (FBS). The Wyeth-calf adapted strain VACV (VR-1536, New York City Department of Health Laboratories) was purchased from the ATCC, amplified in HeLa cells, and quantified while using a VACV titration protocol [40 (link)]. In this study, all of the incubation and infection steps were performed at 37 °C in 5% CO₂, and all chemicals were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), unless otherwise specified.

In this experiment, we used lung cancer cell lines (HCC827, NCI–H358, NCI–H522, NCI– H1299, NCI– H460, and NCI–H226) and HeLa cell line. We purchased the HCC827, NCI–H358, NCI–H522, NCI– H1299, NCI– H460, and HeLa from the Korea Cell Line Bank, and we purchased the NCI–H226 from the American Type Culture Collection. Lung cancer cells (HCC827, NCI–H358, NCI–H522, NCI– H1299, NCI– H460, and NCI–H226) and HeLa cells were maintained in an RPMI 1640 medium (GIBCO BRL, Rockville, MD, USA) with 10% fetal bovine serum and antibiotics (100 units/mL penicillin and 100 mg/mL streptomycin).